Horizon Therapeutics PLC

HZNP:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/22/21 EST
77.40quote price arrow down-0.33 (-0.42%)
Volume
24,426
Close
77.73quote price arrow up+0.30 (+0.39%)
Volume
1,593,193
52 week range
23.81 - 86.67

...

Loading . . .

KEY STATS

  • Open76.81
  • Day High78.22
  • Day Low75.75
  • Prev Close77.43
  • 52 Week High86.67
  • 52 Week High Date10/09/20
  • 52 Week Low23.81
  • 52 Week Low Date03/18/20
  • Market Cap17,155.79M
  • Shares Out220.71M
  • 10 Day Average Volume2.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.06
  • 1 Year % Change109.46

RATIOS/PROFITABILITY

  • EPS (TTM)3.66
  • P/E (TTM)21.23
  • Fwd P/E (NTM)20.89
  • EBITDA (MRQ)625.91M
  • ROE (MRQ)29.59%
  • Revenue (MRQ)1,818.66M
  • Gross Margin (MRQ)74.41%
  • Net Margin (MRQ)43.55%
  • Debt To Equity (MRQ)26.41%

EVENTS

  • Earnings Date02/01/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Horizon Therapeutics PLC News

There is no recent news for this security.

Latest HZNP News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS...
Timothy Walbert
Chairman
Paul Hoelscher
Chief Financial Officer
Andy Pasternak
Executive Vice President
Daniel Camardo
Executive Vice President
Brian Beeler
Executive Vice President
Address
Connaught House
1St Floor, 1 Burlington Road
Dublin
D04 C5Y6
Ireland